Muted performance in US and Ex-US generics and one-off write-off of Aleor's Intangible assets, tumbles sales and profit | Alembic Pharmaceuticals Q1 FY23 Result & Earning Call Highlights

Published on 08 August 2022
.Views 12 .Comments 0

Share On